Loading the section…

CPIX: financial statements from SEC — TradeAlmanac

CPIX

Cumberland Pharmaceuticals Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	45M	38M
Cost of revenue	7M	7M
Research and development	6M	5M
Selling, general and administrative	12M	11M
Operating expenses	47M	44M
Operating income	−3M	−6M
Interest expense	495,990	605,508
Pre-tax income	−3M	−6M
Income tax	40,256	−22,669
Net income	−3M	−6M
Earnings per share	−0.19	−0.46
Earnings per share, diluted	−0.19	−0.46
Weighted average shares	15M	14M
Weighted average shares, diluted	15M	14M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	11M	11M	15M	16M	15M	18M	17M	17M
Receivables	14M	17M	10M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	5M	−612,186
Depreciation and amortisation	4M	5M
Share-based compensation	408,320	301,895
Capital expenditure	97,903	66,461
Investing cash flow	−5M	57,842
Share buybacks	263,478

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator